European Journal of Internal Medicine
Volume 20, Issue 3 , Pages 307-312 , May 2009

Estimation of mortality savings due to a national program for diabetes care

  • Jacob Dreiher

      Affiliations

    • Clalit Health Services, Israel
    • Division of Health in the Community, Ben Gurion University of the Negev, Beer Sheva, Israel
    • Corresponding Author InformationCorresponding author. Division of Health in the Community, Faculty of Health Sciences, Ben Gurion University of the Negev, PO Box 653, Beer Sheva, 84150 Israel. Tel.: +972 3 694 6577/6; fax: +972 3 760 8737.
    • ,
  • Gary Ginsberg

      Affiliations

    • Department of Medical Technology Assessment, Ministry of Health, Jerusalem, Israel
    • ,
  • Gad Rabinowitz

      Affiliations

    • Department of Industrial Engineering and Management, Ben Gurion University of the Negev, Beer Sheva, Israel
    • ,
  • Anat Raskin-Segal

      Affiliations

    • Department of Industrial Engineering and Management, Ben Gurion University of the Negev, Beer Sheva, Israel
    • ,
  • Ron Weitzman

      Affiliations

    • Department of Industrial Engineering and Management, Ben Gurion University of the Negev, Beer Sheva, Israel
    • ,
  • Avi Porath

      Affiliations

    • Clalit Health Services, Israel
    • Department of Epidemiology, Ben Gurion University of the Negev, Beer Sheva, Israel
    • Department of Internal Medicine, Ben Gurion University of the Negev, Beer Sheva, Israel

Received 8 January 2008 ,Revised 28 August 2008 ,Accepted 3 September 2008.

References 

  1. Cook DJ, Guyatt GH. Interpreting, integrating and individualizing evidence about the prevention of diabetic nephropathy. Ann Intern Med. 1991;131:707–708
  2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab Res Clin Pract. 1995;28:103–117
  3. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413–420
  4. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960–967
  5. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431
  6. Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2004;321:405–412
  7. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med. 2005;165:1910–1916
  8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  10. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  11. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diab Care. 2004;27:1330–1334
  12. Saaddine JB, Cadwell B, Gregg W, Engelgau MM, Vinicor F, Imperatore G, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med. 2006;144:465–474
  13. Porath A, Rabinovitz G, Raskin-Segal A, Weitzman R, Ben Said S. In: Quality Indicators for Community Health Care in Israel 2003–2007 Public Report. 2008;http://132.72.100.18/HealthReports/Download/public_report_English_2005-2007.pdf, Accessed 8 August 2008
  14. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–679
  15. Goldfine AB, Beckman JA. Life and death in Denmark: lessons about diabetes and coronary heart disease. Circulation. 2008;117:1914–1917
  16. In: Central Bureau of Statistics. Statistical Abstract of Israel 2006, No. 57, Jerusalem. 2006;http://www1.cbs.gov.il/reader/shnatonenew.htm, Accessed 26 February 2007
  17. Regional Office for Europe. European Health for All Database. http://data.euro.who.int/hfadb/, Accessed 26 February 2007.
  18. Bell DSH. Advances in diabetes for the millennium: the heart and diabetes. Med Gen Med. 2004;6:7
  19. Potts JL, Thomas J. Traditional coronary risk factors in African Americans. Am J Med Sci. 1999;317:189–192
  20. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393
  21. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
  22. Gaede P, Valentine WJ, Palmer AJ, Tucker D, Lammert M, Parving H-H, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the steno-2 study. Diabetes Care. 2008;31(8):1510–1515
  23. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48:868–877
  24. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:89–99
  25. World Health Organization . In: World Health Report 2002 — reducing risks, promoting healthy life. Statistical Annex, Table 4. Geneva; 2002;p. 198–201http://www.who.int/whr/2002/en/whr2002_annex4.pdf, Accessed 2 March 2007
  26. UK Prospective Diabetes Study Group. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ. 1998;317:720–726
  27. Goldfracht M, Porath A. Nationwide program for improving the care of diabetic patients in Israeli primary care centres. Diab Care. 2000;23:495–499
  28. In: HEDIS: The Health plan Employer Data and Information Set (HEDIS). The State of Health Care Quality 2005. NCQA: National Committee for Quality Assurance, USA. 2006;http://www.ncqa.org, Accessed 2 March 2007
  29. Gudbjornsdottir S, Cederholm J, Nilsson PM, Eliasson B for the Steering Committee of the Swedish Diabetes Register. The National Diabetes Register in Sweden: an implementation of the St. Vincent declaration for Quality Improvement in Diabetes Care. Diabetes Care. 2003;26:1270–1276
  30. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:8542–8551
  31. Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia. 2001;44:298–304
  32. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787
  33. Mainous AG, Baker R, Koopman RJ, Saxena S, Diaz VA, Everett CJ, et al. Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia. 2007;50:934–940
  34. Goldie SJ. Chapter 15: Public health and cost-effectiveness analysis. J Natl Cancer Inst Monogr. 2002;31:102–110

PII: S0953-6205(08)00260-4

doi: 10.1016/j.ejim.2008.09.003

European Journal of Internal Medicine
Volume 20, Issue 3 , Pages 307-312 , May 2009

Article Tools

* Image Usage & Resolution